Kidney transplantation – be aware of TCC

Plasma TCC (sC5b-9) is associated with both patient and kidney long-time survival.

 

Nephrologists from aHUS and OUS Rikshospitalet have together with complementologists from NCRG recently presented data in Front Immunol showing data in 900 patients over a 10-year period that increased plasma TCC levels obtained in a stable period at 10 weeks after transplantation  was associated with  patient survival, graft survival and  with death-censored graft loss.

Plasma TCC has again strengthened its position as an important marker in disease pathophysiology, adding another possible indication for complement therapeutic in the future.

Bartlomiej J. Witczak and Søren E. Pieschke were 1st and 2nd authors, and Anders Åsberg and Tom E. Mollnes shared the last authorship.

Here is the link to all authors and the paper – released by Frontiers and will soon be available on PuMed:

Frontiers | Elevated Terminal C5b-9 Complement Complex 10 Weeks Post Kidney Transplantation Was Associated With Reduced Long-Term Patient and Kidney Graft Survival | Immunology (frontiersin.org)

 

Scroll Up

Similar News

Dissemination
Mollnes, Tom Eirik Sep 18. 2026.

Bridging the Gap: Rapid Bedside Complement Testing Brings Lab Innovation to the ICU

Tam Cung and Andreas Barratt-Due in the NCRG has published a paper using a point-of-care assay to detect complement activation...

Read more
Dissemination
Mollnes, Tom Eirik Jun 28. 2026.

Two Norwegian anesthesiologists in NCRG became professors at the University of Oslo

  Søren Erik Pischke was recruited to NCRG as a postdoc in 2014 when he got the prestigious Young Investigators...

Read more
Dissemination
Mollnes, Tom Eirik Feb 10. 2026.

Steinar Kristiansen defended his PhD thesis

Fra venstre: Hovedveileder Tom Eirik Mollnes, biveileder Erik Waage Nielsen, disputasleder Ellinor Haukland, overlege ph.d. Steinar Kristiansen, 1. opponent Olav...

Read more